Guggenheim raised the firm’s price target on Tempus AI (TEM) to $95 from $80 and keeps a Buy rating on the shares. After having met with team members to discuss the company’s development of a foundation model in oncology via a partnership with AstraZeneca (AZN) and privately-held Pathos AI, the firm came away with a better understanding of the project and “why it is so highly differentiated,” the analyst tells investors.
Claim 55% Off TipRanks
New trading tool for TEM bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Cathie Wood Offloads AMD Stock, Boosts Holdings in Alibaba and Baidu
- Cathie Wood Continues Selling Tempus AI and Roku Shares
- Why Is Tempus AI Stock (TEM) Rising in Premarket Trading Today?
- Tempus AI receives FDA clearance for xR RNA-based diagnostic device
- Cathie Wood Continues to Offload Roku and Tempus AI Stocks